Liquid biopsy in non-small cell lung cancer: Highlights and challenges

Erika Rijavec, Simona Coco, Carlo Genova, Giovanni Rossi, Luca Longo, Francesco Grossi

Research output: Contribution to journalReview article

Abstract

Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived markers (i.e., circulating tumor cells, miRNAs, exosomes, and tumor educated platelets) are still at a pre-clinical phase, although they show promising results for their application in screening programs or as prognostic/predictive biomarkers. The main challenges for their clinical translation are the lack of reliable cutoffs and, especially for miRNAs, the great variability among the studies. Moreover, no established tool has been approved for circulating tumor cells and exosome isolation. Finally, large prospective clinical trials are mandatory to provide evidence of their clinical utility.

Original languageEnglish
Article number17
JournalCancers
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Non-Small Cell Lung Carcinoma
Biopsy
Exosomes
Circulating Neoplastic Cells
Neoplasms
MicroRNAs
Biomarkers
Cell Separation
Tumor Biomarkers
Immunotherapy
Early Diagnosis
Cause of Death
Blood Platelets
Clinical Trials
DNA
Therapeutics

Keywords

  • CfDNA/ctDNA
  • Circulating miRNA
  • Exosomes
  • Liquid biopsy
  • NSCLC
  • Prognostic/predictive biomarkers
  • Tumor educated platelets

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liquid biopsy in non-small cell lung cancer : Highlights and challenges. / Rijavec, Erika; Coco, Simona; Genova, Carlo; Rossi, Giovanni; Longo, Luca; Grossi, Francesco.

In: Cancers, Vol. 12, No. 1, 17, 01.2020.

Research output: Contribution to journalReview article

Rijavec, Erika ; Coco, Simona ; Genova, Carlo ; Rossi, Giovanni ; Longo, Luca ; Grossi, Francesco. / Liquid biopsy in non-small cell lung cancer : Highlights and challenges. In: Cancers. 2020 ; Vol. 12, No. 1.
@article{ea9da36b8e954f208591727048960006,
title = "Liquid biopsy in non-small cell lung cancer: Highlights and challenges",
abstract = "Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived markers (i.e., circulating tumor cells, miRNAs, exosomes, and tumor educated platelets) are still at a pre-clinical phase, although they show promising results for their application in screening programs or as prognostic/predictive biomarkers. The main challenges for their clinical translation are the lack of reliable cutoffs and, especially for miRNAs, the great variability among the studies. Moreover, no established tool has been approved for circulating tumor cells and exosome isolation. Finally, large prospective clinical trials are mandatory to provide evidence of their clinical utility.",
keywords = "CfDNA/ctDNA, Circulating miRNA, Exosomes, Liquid biopsy, NSCLC, Prognostic/predictive biomarkers, Tumor educated platelets",
author = "Erika Rijavec and Simona Coco and Carlo Genova and Giovanni Rossi and Luca Longo and Francesco Grossi",
year = "2020",
month = "1",
doi = "10.3390/cancers12010017",
language = "English",
volume = "12",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "1",

}

TY - JOUR

T1 - Liquid biopsy in non-small cell lung cancer

T2 - Highlights and challenges

AU - Rijavec, Erika

AU - Coco, Simona

AU - Genova, Carlo

AU - Rossi, Giovanni

AU - Longo, Luca

AU - Grossi, Francesco

PY - 2020/1

Y1 - 2020/1

N2 - Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived markers (i.e., circulating tumor cells, miRNAs, exosomes, and tumor educated platelets) are still at a pre-clinical phase, although they show promising results for their application in screening programs or as prognostic/predictive biomarkers. The main challenges for their clinical translation are the lack of reliable cutoffs and, especially for miRNAs, the great variability among the studies. Moreover, no established tool has been approved for circulating tumor cells and exosome isolation. Finally, large prospective clinical trials are mandatory to provide evidence of their clinical utility.

AB - Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived markers (i.e., circulating tumor cells, miRNAs, exosomes, and tumor educated platelets) are still at a pre-clinical phase, although they show promising results for their application in screening programs or as prognostic/predictive biomarkers. The main challenges for their clinical translation are the lack of reliable cutoffs and, especially for miRNAs, the great variability among the studies. Moreover, no established tool has been approved for circulating tumor cells and exosome isolation. Finally, large prospective clinical trials are mandatory to provide evidence of their clinical utility.

KW - CfDNA/ctDNA

KW - Circulating miRNA

KW - Exosomes

KW - Liquid biopsy

KW - NSCLC

KW - Prognostic/predictive biomarkers

KW - Tumor educated platelets

UR - http://www.scopus.com/inward/record.url?scp=85077200220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077200220&partnerID=8YFLogxK

U2 - 10.3390/cancers12010017

DO - 10.3390/cancers12010017

M3 - Review article

AN - SCOPUS:85077200220

VL - 12

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

M1 - 17

ER -